Understanding GAS8-AS1: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

Target Name: GAS8-AS1

NCBI ID: G750

GAS8-AS1

Understanding GAS8-AS1: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

GAS8-AS1 (C16orf3) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and expression patterns have made it an attractive target for researchers to study, and recent studies have shed light on its potential role in the development and progression of these diseases.

GAS8-AS1 is a short non-coding RNA molecule that consists of 8 exons and is located in the 16th chromosome. It is characterized by a unique structure that consists of a single open reading frame (ORF) that is primarily composed of alternating between GAG and AUG codons. GAS8-AS1 has a length of 292 nucleotides and an estimated transcriptional level of 1.15 kilobases (kb).

GAS8-AS1 is expressed in various tissues and cells, including human tissues, tissues of mouse models, and cancer cell lines. Its expression patterns vary depending on the cell type and the context in which it is expressed. For example, GAS8-AS1 is Highly expressed in the human breast tissue, and its expression levels decrease in the human prostate tissue. Additionally, GAS8-AS1 is expressed in various cancer types, including lung, breast, and colon cancer.

One of the reasons why GAS8-AS1 has been identified as a potential drug target is its unique expression patterns. Unlike many other RNA molecules, GAS8-AS1 is not expressed in all cell types, which makes it a more reliable target for drugs that are specific to certain cell types. Additionally, its expression patterns are consistent with the known functions of its coding gene, which has not been fully characterized.

GAS8-AS1 has been shown to play a role in various cellular processes, including cell growth, apoptosis, and transcriptional regulation. For example, GAS8-AS1 has been shown to be involved in the regulation of cell apoptosis, as it has been shown to induce apoptosis in cancer cells. Additionally, GAS8-AS1 has been shown to play a role in the regulation of cell growth, as it has been shown to inhibit the growth of cancer cells.

Another reason why GAS8-AS1 has been identified as a potential drug target is its unique structure. Unlike many other RNA molecules, GAS8-AS1 has a unique 3' end that consists of a terminal open reading frame (ORF) extension. This extension is thought to play a role in the stability and stability of the RNA molecule, and may be a potential target for drugs that can modify its stability.

In addition to its unique structure and expression patterns, GAS8-AS1 has also been shown to play a role in the development and progression of various diseases. For example, GAS8-AS1 has been shown to be involved in the development and progression of cancer, as it has been shown to promote the growth and survival of cancer cells. Additionally, GAS8-AS1 has also been shown to be involved in the development and progression of neurodegenerative diseases, as it has been shown to contribute to the progression of neurodegenerative diseases.

In conclusion, GAS8-AS1 is a unique and promising molecule that has the potential to be a drug target and biomarker for various diseases. Its unique structure and expression patterns, as well as its involvement in various cellular processes and its role in the development and progression of diseases make it an attractive target for researchers to study. Further studies are needed to fully understand its potential role in these diseases and to develop safe and effective drugs that can target GAS8-AS1.

Protein Name: GAS8 Antisense RNA 1

The "GAS8-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GAS8-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets